Ana Maria Gonzalez-Angulo
Overview
Explore the profile of Ana Maria Gonzalez-Angulo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
76
Citations
6128
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Evans K, Yuca E, Scott S, Zhao M, Arango N, Cruz Pico C, et al.
Cancer Res
. 2021 Sep;
81(21):5572-5581.
PMID: 34518211
Oxidative phosphorylation (OXPHOS) is an active metabolic pathway in many cancers. RNA from pretreatment biopsies from patients with triple-negative breast cancer (TNBC) who received neoadjuvant chemotherapy demonstrated that the top...
2.
Akcakanat A, Zheng X, Cruz Pico C, Kim T, Chen K, Korkut A, et al.
Clin Cancer Res
. 2021 Mar;
27(11):3243-3252.
PMID: 33782032
Purpose: Metastatic breast cancer (MBC) is not curable and there is a growing interest in personalized therapy options. Here we report molecular profiling of MBC focusing on molecular evolution in...
3.
Xing Y, Lin N, Maurer M, Chen H, Mahvash A, Sahin A, et al.
Breast Cancer Res
. 2019 Jul;
21(1):78.
PMID: 31277699
Background: The PI3K/AKT pathway is activated through PIK3CA or AKT1 mutations and PTEN loss in breast cancer. We conducted a phase II trial with an allosteric AKT inhibitor MK-2206 in...
4.
Arango N, Yuca E, Zhao M, Evans K, Scott S, Kim C, et al.
Breast Cancer Res
. 2017 Aug;
19(1):93.
PMID: 28810913
Background: Selinexor (KPT-330) is an oral agent that has been shown to inhibit the nuclear exporter XPO1. Given the pressing need for novel therapies for triple-negative breast cancer (TNBC), we...
5.
Trape A, Liu S, Cortes A, Ueno N, Gonzalez-Angulo A
J Cancer
. 2016 Jun;
7(8):947-56.
PMID: 27313785
Among patients with hormone receptor (HR)-positive breast cancer, those with residual disease after neoadjuvant chemotherapy have a higher risk of relapse and poorer survival than those with a complete response....
6.
Chae Y, Gagliato D, Pai S, Carneiro B, Mohindra N, Giles F, et al.
PLoS One
. 2016 Apr;
11(4):e0152585.
PMID: 27055285
EGFR and cMET cross-talk is involved in breast cancer (BC) progression and resistance to different targeted therapies, however little is known about the co-expression patterns of EGFR and cMET or...
7.
McAuliffe P, Evans K, Akcakanat A, Chen K, Zheng X, Zhao H, et al.
PLoS One
. 2016 Mar;
11(3):e0151121.
PMID: 26953790
No abstract available.
8.
McAuliffe P, Evans K, Akcakanat A, Chen K, Zheng X, Zhao H, et al.
PLoS One
. 2015 Sep;
10(9):e0136851.
PMID: 26325287
Background: Breast cancer patients who are resistant to neoadjuvant chemotherapy (NeoCT) have a poor prognosis. There is a pressing need to develop in vivo models of chemo resistant tumors to...
9.
Hughes R, Qian B, Rowan C, Muthana M, Keklikoglou I, Olson O, et al.
Cancer Res
. 2015 Aug;
75(17):3479-91.
PMID: 26269531
Tumor relapse after chemotherapy-induced regression is a major clinical problem, because it often involves inoperable metastatic disease. Tumor-associated macrophages (TAM) are known to limit the cytotoxic effects of chemotherapy in...
10.
Raghav K, Gonzalez-Angulo A, Blumenschein Jr G
Transl Lung Cancer Res
. 2015 Mar;
1(3):179-93.
PMID: 25806180
Lung cancer is the number one cause of cancer related mortality with over 1 million cancer deaths worldwide. Numerous therapies have been developed for the treatment of lung cancer including...